Bodenheimer T. Uneasy alliance: Clinical investigators and the pharmaceutical industry. N Engl J Med.2000;342:1539-1544.
Relman AS, Angell M. America's other drug problem: how the drug industry distorts medicine
and politics. New Republic.2002;227:27-41.
DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ.2003;22:151-185.
Gelijns AC, Thier SO. Medical innovation and institutional interdependence: rethinking university-industry
Lievre M, Menard J, Bruckert E.
et al. Premature discontinuation of clinical trial for reasons not related
to efficacy, safety, or feasibility. BMJ.2001;322:603-605.
Psaty BM, Rennie D. Stopping medical research to save money. A broken pact with researchers
and patients. JAMA2003;289:2128-2131.
Evans S, Pocock S. Societal responsibilities of clinical trial sponsors. BMJ.2001;322:569-570.
Boyd K. Early discontinuation violates Helsinki principles. BMJ.2001;322:605-606.
World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. JAMA.2000;284:3043-3045.
Rao JN, Sant Cassia LJ. Ethics of undisclosed payments to doctors recruiting patients in clinical
Boyd EA, Bero LA. Assessing faculty financial relationships with industry: a case study. JAMA.2000;284:2209-2214.
Coyle SL. Physician-industry relations, I: Individual physicians. Ann Intern Med.2002;136:396-402.
Montaner JSG, O'Shaughnessy MV, Schechter MT. Industry-sponsored clinical research: a double-edged sword. Lancet.2001;358:1893-1895.
Moses H, Braunwald E, Martin JB, Thier SO. Collaborating with industry—choices for the academic medical
center. N Engl J Med.2002;347:1371-1375.
Davidson RA. Source of funding and outcome of clinical trials. J Gen Intern Med.1986;1:155-158.
Rochon PA, Gurwitz JH, Simms RW.
et al. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory
drugs in the treatment of arthritis. Arch Intern Med.1994;154:157-163.
Cho MK, Bero LA. The quality of drug studies published in symposium proceedings. Ann Intern Med.1996;124:485-489.
Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL. Evaluation of conflict of interest in economic analyses of new drugs
used in oncology. JAMA.1999;282:1453-1457.
Bero LA, Rennie D. Influences on the quality of published drug studies. Int J Technol Assess Health Care.1996;12:209-237.
Verhagen AP, de Vet HCW, de Bie RA.
et al. The Delphi list: a criteria list for quality assessment of randomized
clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol.1998;51:1235-1241.
Djulbegovic B, Lacevic M, Cantor A.
et al. The uncertainty principle and industry-sponsored research. Lancet.2000;356:635-638.
Findlay SD. Direct-to-consumer promotion of prescription drugs: Pharmacoeconomics.2001;19:109-119.
Chalmers I. Underreporting research is scientific misconduct. JAMA.1990;263:1405-1408.
Dong BJ, Hauck WW, Gambertoglio JG.
et al. Bioequivalence of generic and brand-name levothyroxine products in
the treatment of hypothyroidism. JAMA.1997;277:1205-1213.
Vogel G. Long-suppressed study finally sees light of day. Science.1997;276:525-526.
Niiler E. Company, academics argue over data. Nature Biotech.2000;18:1235.
Nathan DG, Weatherall DJ. Academic freedom in clinical research. N Engl J Med.2002;347:1368-1371.
Begg C, Cho M, Eastwood S.
et al. Improving the quality of reporting of randomized controlled trials:
the CONSORT statement. JAMA.1996;276:637-639.
Davidoff F, DeAngelis CD, Drazen JM.
et al. Sponsorship, authorship, and accountability. JAMA.2001;286:1232-1234.
Johns MME, Barnes M, Florencio PS. Restoring balance to industry-academia relationships in an era of institutional
financial conflicts of interest: promoting research while maintaining trust. JAMA.2003;289:741-746.